ReviewAnnals of the New York Academy of Sciences2006
Severe acute respiratory syndrome (SARS): development of diagnostics and antivirals.
Review in Annals of the New York Academy of Sciences, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 53 citations in OpenAlex.
- Tea Polyphenols in the COVID-19 Era: Mechanistic Insights and Translational Challenges.Current issues in molecular biology · 2026Review
- The future of severe acute respiratory syndrome-cornavirus and coronavirus disease.World journal of pediatrics : WJP · 2026Article
- Host susceptibilities and entry processes of SARS-CoV-2 Omicron variants using pseudotyped viruses carrying spike protein.BMC veterinary research · 2025Article
- Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.Journal of medical virology · 2024Article
- MERS-CoV-nsp5 expression in human epithelial BEAS 2b cells attenuates type I interferon production by inhibiting IRF3 nuclear translocation.Cellular and molecular life sciences : CMLS · 2024Article
- Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches.Biochemistry and biophysics reports · 2024Article
- Asymmetry in the peak in Covid-19 daily cases and the pandemic R-parameter.medRxiv : the preprint server for health sciences · 2023Article
- Using postal change-of-address data to predict second waves in infections near pandemic epicentres.Epidemiology and infection · 2022Article
- Evaluation of Betacoronavirus OC43 and SARS-CoV-2 Elimination by Zefero Air Sanitizer Device in a Novel Laboratory Recirculation System.Pathogens (Basel, Switzerland) · 2022Article
- A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- A Narrative Review of COVID-19 Vaccines.Vaccines · 2021Review
- Subacute thyroiditis after SARS-CoV-2 infection.Clinical case reports · 2021Article
- Utilizing the VirIdAl Pipeline to Search for Viruses in the Metagenomic Data of Bat Samples.Viruses · 2021Article
- IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.Viruses · 2021Article
- Design and finite element simulation of metal-core piezoelectric fiber/epoxy matrix composites for virus detection.Sensors and actuators. A, Physical · 2021Article
- Discovery of Antivirals Using Phage Display.Viruses · 2021Review
- A genomic region associated with protection against severe COVID-19 is inherited from Neandertals.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Children were less frequently infected with SARS-CoV-2 than adults during 2020 COVID-19 pandemic in Warsaw, Poland.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.Scientific data · 2021Article
- A single nucleotide distinguishes the SARS-CoV-2 in the Wuhan outbreak in December 2019 from that in Beijing-Xinfadi in June 2020, China.New microbes and new infections · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The previously unknown coronavirus that caused severe acute respiratory syndrome (SARS-CoV) affected more than 8,000 persons worldwide and was responsible for more than 700 deaths during the first outbreak in 2002-2003. For reasons unknown, the SARS virus is less severe and the clinical progression a great deal milder in children younger than 12 years of age. In contrast, the mortality rate can exceed 50% for persons at or above the age of 60. As part of the Sino-European Project on SARS Diagnostics and Antivirals (SEPSDA), an immune phage-display library is being created from convalescent patients in a phagemid system for the selection of single-chain fragment variables (scFv) antibodies recognizing the SARS-CoV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.